前列腺床大分割放疗联合IMRT的2期试验
这项2期试验评估根治性前列腺切除术后对前列腺床行大分割放疗的安全性,处方剂量51 Gy分15次(每次3.4 Gy),采用IMRT和图像引导技术。61例可评估患者中,急性≥2级泌尿毒性11.5%、胃肠毒性13.1%,晚期≥2级泌尿毒性8.2%、胃肠毒性11.5%,无3级胃肠不良事件;中位随访16个月,2年生化失败无生存率95.1%。结论认为该方案安全,毒性可接受,需大样本随机试验进一步验证。
要点
- 术后前列腺床大分割放疗51 Gy/15次,急性≥2级泌尿毒性11.5%、胃肠毒性13.1%。
- 晚期≥2级泌尿毒性8.2%、胃肠毒性11.5%,无3级胃肠不良事件。
- 中位随访16个月,2年生化失败无生存率95.1%,无后续挽救治疗和转移。
核心结论
- 前列腺床大分割放疗15次安全,泌尿和胃肠毒性谱可接受,但需大样本随机试验进一步研究。
研究设计与样本
- 2期前瞻性试验纳入64例根治性前列腺切除术后患者,61例接受辅助或挽救性前列腺床大分割放疗。
- 处方剂量51 Gy分15次(每次3.4 Gy),采用调强放疗和图像引导放疗技术。
- 主要终点为急性≥2级泌尿毒性发生率,次要终点包括急性和晚期泌尿/胃肠毒性、生化失败无生存率、无转移生存、肿瘤特异生存、总生存及健康相关生活质量。
主要发现
- 61例接受放疗的患者中57例为挽救性、4例为辅助性;中位随访16个月。
- 急性≥2级泌尿症状发生率11.5%,急性≥2级胃肠症状发生率13.1%。
- 晚期≥2级泌尿毒性发生率8.2%,1例(1.6%)同时发生急性和晚期3级泌尿毒性。
- 晚期≥2级胃肠毒性发生率11.5%,未报告3级胃肠不良事件。
- 2年生化失败无生存率95.1%,后续挽救治疗使用率0%,转移发生率0%。
关键数值与推荐
- 处方剂量为51 Gy分15次,每次3.4 Gy。
- 主要终点急性≥2级泌尿毒性发生率为11.5%。
- 急性≥2级胃肠毒性发生率为13.1%,晚期≥2级泌尿毒性发生率为8.2%,晚期≥2级胃肠毒性发生率为11.5%。
- 2年生化失败无生存率为95.1%,后续挽救治疗使用率和转移发生率均为0%。
临床怎么用
- 根治性前列腺切除术后选择辅助或挽救性前列腺床放疗时,可考虑51 Gy/15次的大分割方案,但需结合图像引导和调强技术。
- 治疗中及随访时应重点监测泌尿和胃肠毒性,尤其是≥2级事件及罕见3级泌尿毒性。
- 当前随访时间短,肿瘤学结局需谨慎解读,不宜据此常规改变实践,应等待更大样本随机试验结果。
局限性
- 随访时间短(中位16个月),限制了对肿瘤学终点的可靠评估。
- 为单臂2期试验,样本量有限(61例接受放疗),需大样本随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Postoperative radiation therapy (RT) is a common therapy used for patients with prostate cancer. Although clinical trials have established the safety and efficacy of hypofractionation as a primary therapy, there are limited data in a postoperative setting. We conducted a prospective trial to evaluate the safety and feasibility of postoperative hypofractionated RT to the prostate bed. METHODS AND MATERIALS: In this phase 2 trial, patients submitted to radical prostatectomy were treated with hypofractionated RT to the prostate bed (adjuvant or salvage). The prescribed dose was 51 Gy in 15 fractions (3.4 Gy per fraction), using intensity modulated and image guided radiation therapy techniques. The primary endpoint was the rate of acute genitourinary (GU) grade ≥2 toxicity. Secondary endpoints included acute gastrointestinal (GI) and late GU/GI toxicities, biochemical failure-free survival (BFFS), metastasis-free survival, cancer-specific survival, overall survival, and health-related quality of life. RESULTS: Of 64 enrolled patients, 61 received radiation therapy (57 salvage and 4 adjuvant radiation therapy). After a median follow-up of 16 months, 11.5% of patients experienced acute grade ≥2 GU symptoms and 13.1% experienced acute grade ≥2 GI symptoms. The late grade ≥2 GU toxicity rate was 8.2%, and 1 patient (1.6%) developed both acute and late grade 3 GU toxicity. The late grade ≥2 GI toxicity rate was 11.5%, and no grade 3 GI adverse events were reported. The short follow-up limits our ability to perform a robust oncologic endpoint assessment; however, the 2-year BFFS, use of subsequent salvage therapy, and the development of metastasis were 95.1%, 0%, and 0%, respectively. CONCLUSIONS: Hypofractionated RT to the prostate bed in 15 treatments was safe, with an acceptable GU and GI toxicity profile. Further study in large, randomized trials is warranted.
引用
- Leite ETT, Ramos CCA, Ribeiro VAB, et al. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 33346091. doi:10.1016/j.ijrobp.2020.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。